The market opened in the red on April 13, 2020. The previous trading session witnessed the Sensex going up by 4.23 percent to end at 31,159.27 and the Nifty was up 4.1 percent to close at 9,111.

The market opened in the red on April 13, 2020. The previous trading session witnessed the Sensex going up by 4.23 percent to end at 31,159.27 and the Nifty was up 4.1 percent to close at 9,111.

The market opened in the red on April 13, 2020, overall volumes in futures & options currently stand at 3,63 crore contracts with a turnover of Rs. 17,88,472.01 crore.

The market opened in the red on April 13, 2020, overall volumes in futures & options currently stand at 3,63 crore contracts with a turnover of Rs. 17,88,472.01 crore.

The investment in this subsidiary was intended to unlock value in the global injectable markets. The subsidiary has been given an approval for its abbreviated new drug application (ANDA) Ropivacaine Hydrochloride injection USP from USFDA.

In a fight against the deadly Coronavirus the company set to put in its efforts by manufacturing portable ventilators, the company said in a press release to the stock exchanges.

On Friday, the stock had given a breakout above the neckline of double bottom formation, backed by strong volumes. Additionally, the stock formed a sizeable bullish candle on the breakout day, which adds further strength to the breakout. 

There are chances this counter trend rally may extend towards 9,400-9,600 zone. However, we would advise the traders to exercise caution at higher levels. Stocks in news: Gujarat Alkalies & Chemicals, Transgene Biotek, Camlin Fine Sciences, Cadila Healthcare, Lasa Supergenerics.

Welcome to Dalal Street after a long weekend. Today, Indian markets will be back to work.  The beginning of the week seems to be a tepid one as the early indications by SGX Nifty show that markets are set for an insipid start. SGX Nifty trades down by 50 points at 9,056 levels.

Punjab & Sind Bank announced that its board is planning to raise equity capital next week via QIP and preferential issue.